← Human Trials & Peer-Reviewed Studies
Association and linkage between an insulin-like growth factor-1 gene polymorphism and fat free mass in the HERITAGE Family Study
Plain-language guide to PMID 10490798 (1999): controlled clinical trial study of IGF-1 LR3 in 502 individuals.
Key Facts
- PMID
- 10490798
- Journal
- International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
- Year
- 1999
- Study type
- Controlled Clinical Trial
- Authors
- Sun G et al. (11 authors)
- DOI
- 10.1038/sj.ijo.0801021
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this controlled clinical trial publication.
To investigate the relationship between a DNA microsatellite marker in the insulin-like growth factor-1 (IGF-1) gene and body composition phenotypes before and following exposure to 20 weeks of aerobic exercise training in the HERITAGE Family Study.
Who Took Part
According to the abstract, 502 individuals were involved.
PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.
A maximum of 502 Caucasian individuals (99 families; 190 parents and 312 adult offspring).
How the Study Was Run
A controlled intervention study: fat mass (FM), percentage body fat (%FAT), fat free mass (FFM), body mass index (BMI) and abdominal visceral fat (AVF) at baseline (B) and in response to training (delta=post minus pre-training value) were measured.
Association and sib-pair linkage studies were undertaken.
The polymorphism was typed by polymerase chain reaction and DNA sequencer.
The body composition phenotypes were determined from the underwater weighing method, and AVF was assessed by computerized tomography scan.
What Was Measured
Topics PubMed links to this paper include Analysis of Variance, Arizona, Body Composition, DNA, DNA Primers, Dinucleotide Repeats and Exercise.
What This Means in Plain Language
This is a controlled clinical trial of IGF-1 LR3 in 502 individuals.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1999 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.